Literature DB >> 8952515

Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites.

G Steiner1, D Sidransky.   

Abstract

In the last decade, specific chromosomal alterations have been associated with different tumor types. These aberrations were originally detected by karyotyping and then by more sophisticated cytogenetic analysis. A few karyotypic alterations can be directly linked to distinct malignancies, such as the Philadelphia chromosome in acute lymphoblastic leukemia, loss of distal chromosome 3p 14 in small-cell lung cancer, the loss of distal chromosome 11p13 in Wilms' tumor, and loss or rearrangement of the short arm of chromosome 3 in clear and chromophobe RCC. The relative specificity of the latter findings enabled investigators to diagnose an occult renal clear-cell carcinoma from a supraclavicular lymph node metastasis by analysis of G-banded metaphase chromosomes obtained from this mass. A similar report based also on cytogenetic findings was published earlier. Karyotypic changes, however, detect only gross alterations visible to an observer. With more refined diagnostic tools, such as microsatellite analysis, other, even smaller, well defined lesions can be analyzed. A summary of the known frequencies of chromosomal losses is given in Table 1. The combination of certain LOH patterns has shown great promise in the differential diagnosis of renal tumors. The transfer of molecular genetics from the laboratory to surgical pathology and other clinical departments is a meaningful event and a challenging task. Molecular pathology is certain to become important in the diagnosis of tumors with unclear histology. Diagnosis based widely upon staining techniques and determination of a patient's prognosis by staging and grading alone will be increasingly accompanied by molecular genetic methods. Pathology may be on the verge of the greatest change since the introduction of the microscope.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8952515      PMCID: PMC1865338     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Diagnosis of primary renal cell carcinoma in a left supraclavicular lymph node by chromosome analysis.

Authors:  P Dal Cin; R Sciot; I De Wever; B Van Damme; H Van den Berghe
Journal:  J Urol       Date:  1996-07       Impact factor: 7.450

2.  Distal nephron renal tumors: microsatellite allelotype.

Authors:  T J Polascik; P Cairns; J I Epstein; L Fuzesi; J Y Ro; F F Marshall; D Sidransky; M Schoenberg
Journal:  Cancer Res       Date:  1996-04-15       Impact factor: 12.701

3.  Hereditary renal-cell carcinoma associated with a chromosomal translocation.

Authors:  A J Cohen; F P Li; S Berg; D J Marchetto; S Tsai; S C Jacobs; R S Brown
Journal:  N Engl J Med       Date:  1979-09-13       Impact factor: 91.245

4.  Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis.

Authors:  P Bugert; G Kovacs
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

5.  Fluorescence in situ hybridization analysis of renal oncocytoma reveals frequent loss of chromosomes Y and 1.

Authors:  J A Brown; S Takahashi; A Alcaraz; T J Borell; K L Anderl; J Qian; D L Persons; D G Bostwick; M M Lieber; R B Jenkins
Journal:  J Urol       Date:  1996-07       Impact factor: 7.450

6.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.

Authors:  P Cairns; T J Polascik; Y Eby; K Tokino; J Califano; A Merlo; L Mao; J Herath; R Jenkins; W Westra; J L Rutter; A Buckler; E Gabrielson; M Tockman; K R Cho; L Hedrick; G S Bova; W Isaacs; W Koch; D Schwab; D Sidransky
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

7.  Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics.

Authors:  W Thoenes; S Störkel; H J Rumpelt
Journal:  Pathol Res Pract       Date:  1986-05       Impact factor: 3.250

8.  5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.

Authors:  A Merlo; J G Herman; L Mao; D J Lee; E Gabrielson; P C Burger; S B Baylin; D Sidransky
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

9.  Chromophobe cell renal carcinoma and its variants--a report on 32 cases.

Authors:  W Thoenes; S Störkel; H J Rumpelt; R Moll; H P Baum; S Werner
Journal:  J Pathol       Date:  1988-08       Impact factor: 7.996

10.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

View more
  4 in total

1.  Loss of heterozygosity assay for molecular detection of cancer using energy-transfer primers and capillary array electrophoresis.

Authors:  I L Medintz; C C Lee; W W Wong; K Pirkola; D Sidransky; R A Mathies
Journal:  Genome Res       Date:  2000-08       Impact factor: 9.043

2.  Development and validation of a microRNA-based diagnostic assay for classification of renal cell carcinomas.

Authors:  Yael Spector; Eddie Fridman; Shai Rosenwald; Sofia Zilber; Yajue Huang; Iris Barshack; Orit Zion; Heather Mitchell; Mats Sanden; Eti Meiri
Journal:  Mol Oncol       Date:  2013-03-26       Impact factor: 6.603

3.  Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients.

Authors:  Xiaojie Tan; Songqin He; Yifang Han; Yongwei Yu; Jianru Xiao; Danfeng Xu; Guoping Wang; Yan Du; Wenjun Chang; Jianhua Yin; Tong Su; Jianguo Hou; Guangwen Cao
Journal:  Cancer Cell Int       Date:  2013-02-26       Impact factor: 5.722

4.  Virtual karyotyping with SNP microarrays reduces uncertainty in the diagnosis of renal epithelial tumors.

Authors:  Jill M Hagenkord; Anil V Parwani; Maureen A Lyons-Weiler; Karla Alvarez; Robert Amato; Zoran Gatalica; Jose M Gonzalez-Berjon; Leif Peterson; Rajiv Dhir; Federico A Monzon
Journal:  Diagn Pathol       Date:  2008-11-06       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.